GEMIN2

Across TCGA pan-cancer cohorts, GEMIN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GEMIN2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GEMIN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GEMIN2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, CCRCC, and OV are the cancer types where GEMIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.862	0.391	.010	21	view →
CCRCC	DFS	Median	All	0.721	1.000	.021	13	view →
OV	DFS	Median	All	0.841	1.000	.029	12	view →
LSCC	OS	Quartile	II,III,IV	0.944	0.449	.002	11	view →
PDAC	DFS	Tertile	II,III,IV	0.502	0.314	.032	10	view →
HNSC	OS	Median	IV	0.739	0.944	.004	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GEMIN2–LUAD (DFS)

Open the LUAD breakdown →